DDR2 and non-small cell lung carcinoma: In 67% of these cases, we identified TP53-mutations, while 60% of them carried co-mutations in either MET, KRAS, NRAS, SMAD4, PIK3CA, CTNNB1, DDR2, ERBB4, FGFR1, or FGFR3. Other analyses of gefitinib- and erlotinib-treated EGFRM+ NSCLC cohorts using the same targeted NGS platform as ours showed co-mutations in analogous genes and at very similar frequency [52,53,117,118].